OMER - Omeros: The Prognosis Brightens
Love is like war: easy to begin but very hard to stop." - H. L. Mencken
Omeros (OMER) has one of the biggest love/hate followings in the biotech sector. There are bulls who believe that if its primary drug candidate OMS721 is approved for any one or possibly two indications of the five it is currently targeting, the compound could be a blockbuster.
Others such as the notorious Adam Feuerstein have derided the drug's potential and cast suspicion on how the management has presented trial data. A few went